Athens 30/05/2023: Dimitris Moraitis has assumed the duties of , General Manager of Tikun Olam Europe. TIKUN OLAM Europethe leading pharmaceutical industry in the research, development, production and distribution of medicinal cannabis products in Greece, which will come into force on June 1st ... .
Dimitris Moraitis career spans more than 27 years in the Greek and Multinational pharmaceutical sector in significant positions of responsibility, such as General Manager of VIAN S.A., President of EfEX (The Greek association of Self-Care Industry), Board Member of AESPG (the European association of Self-Care Industry), and Vice President of SEPTEDE (Association of Children's Food & Special Nutrition Companies of Greece). He has studied at School of Pharmacy of the National & Kapodistrian University of Athens, the School of Pharmacy of the University of Parma (Parma, Italy), and holds a Master’s in Management from the University of Heartfordshire (London, England).
Mr. Nikos Beis, CEO of Tikun Olam Europe stated: "We welcome with great enthusiasm Mr. Dimitris Moraitis as the new , General Manager of Tikun Olam Europe. His proven ability/capacity to successfully lead teams and drive business growth make him an invaluable addition to our company. We are looking forward to applying his experience and expertise to expand Tikun Olam Europe in the Greek and wider European markets."
Mr.Dimitris Moraitis, General Manager of of Tikun Olam Europe stated: "It is a great pleasure and honour to be part of Tikun Olan Europe, a strong team in the field of medicinal cannabis. My goal is to contribute substantially to the dynamic growth of the company and the continuation of its successful course in Greece and subsequently in the European market, producing high quality products, ensuring that patients around the world will have access to safe and effective pharmaceutical formulations ".
Regarding TIKUN OLAM
TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.
About TIKUN OLAM EUROPE
TIKUN's OLAM presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.
With a total investment of €40m, in a 56,000m2 area in Corinth,2 in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with hi-tech equipment.
TIKUN’s OLAM EUROPE activity is fully aligned with the Greek legislation provisions for the cultivation and processing of cannabis, aiming at the creation of pharmaceutical formulations that will be produced in a EU-GMP environment and by applying strict control standards and procedures which ensure high quality and safety.
The company utilizes TIKUN’s OLAM know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real Clinical Practice Data (RWD).
In addition, TIKUN OLAM EUROPE has been on the market since the beginning of 2022 and the TIKUN CBD product line and from 2023 the product line LIFELAB CBD. Both of them are produced in a certified factory in France, based on innovative formulas developed by TIKUN’s OLAM EUROPE R&D division. The exclusive distribution of the CBD product lines has been undertaken by PHARMASERV-LILLY and LAVIPHARM respectively. Both product line series acts on the annoyances of everyday life, while at the same time benefiting the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.
V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / +30 6936775484 - Email email@example.com